RTP Mobile Logo
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Prostate Cancer (Webinar Video Proceedings)
Released March 2022

Featuring perspectives from Drs Neeraj Agarwal, Himisha Beltran, Fred Saad and A Oliver Sartor, moderated by Dr Alan Bryce. Published March 2, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.


    • Appraise published research findings on and current guideline recommendations for optimal management approaches to biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of systemic therapy.
    • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
    • Explore available and emerging data with treatment intensification with cytotoxic and secondary hormonal therapy for metastatic hormone-sensitive prostate cancer, and effectively integrate these approaches into clinical management algorithms.
    • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
    • Assess the available and emerging research database supporting the use of PARP inhibitors for patients with mCRPC, and discern how to optimally incorporate these agents into current and future clinical management algorithms.
    • Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with progressive PSMA-positive mCRPC, and consider the clinical role of this strategy.
    • Recall available research data and ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:


    Neeraj Agarwal, MD
    Professor of Medicine
    Senior Director for Clinical Research Innovation
    Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
    Director, Center of Investigational Therapeutics
    Director, Genitourinary Oncology Program
    Huntsman Cancer Institute, University of Utah (NCI-CCC)
    Salt Lake City, Utah

    Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc.

    Himisha Beltran, MD
    Associate Professor of Medicine
    Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology
    Director of Translational Research, Medical Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Astellas, Amgen Inc, Blue Earth Diagnostics, Foundation Medicine, Janssen Biotech Inc, Merck, Oncorus, Pfizer; Consulting Agreement: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

    Fred Saad, MD, FRCS
    Professor and Chairman of Urology
    Director of GU Oncology
    Raymond Garneau Chair in Prostate Cancer
    University of Montreal Hospital Center (CHUM)
    Montréal, Québec

    Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme.

    A Oliver Sartor, MD
    Laborde Professor for Cancer Research
    Medical Director, Tulane Cancer Center
    Associate Dean for Oncology
    Tulane Medical School
    New Orleans, Louisiana

    Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals,TeneoBio, Theragnostics; Contracted Research: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Endocyte Inc, Invitae, Janssen Biotech Inc, Lantheus, Merck, Progenics Pharmaceuticals Inc, TeneoBio; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Myovant Sciences.


    Alan H Bryce, MD
    Chair, Division of Hematology and Medical Oncology
    Chair, Genitourinary Disease Group
    Mayo Clinic
    Phoenix, Arizona

    Advisory Committee: Merck; Contracted Research: Janssen Biotech Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

    Release date: March 2022
    Expiration date: March 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):